Lynparza, a big change in the tx of BRCA-mutated cancer

5th anniversary meeting, reduce the risk of death from taking drugs

Proven excellent effect in real-world for Koreans

"Most ovarian cancers are found in the 3rd to 4th stage because there is no subjective symptoms.

 

After the first treatment, 70% recur within 3 years, and the 5-year survival rate is only 38%.

 

Maintained by the release of Lynparza.

 

The prognosis of patients is greatly improved through therapy.

 

In particular, the first published 5-year follow-up result among PARP inhibitors suggests the possibility of long-term survival of ovarian cancer."

Professor Byungki Kim

Byung-ki Kim, Professor of obstetrics and gynecology, University College of Medicine, told a press conference on the 27th that the appearance of the first PARP inhibitor Lynparza (Olaparib) had on the treatment of ovarian cancer.

 

On this day, AstraZeneca Korea held an online press conference on the topic of Lynparza's clinical value and significance in the field of ovarian cancer treatment, in celebration of the 5th anniversary of Lynparza's launch in Korea.

 

Lynparza, launched in Korea in August 2015, is a targeted anticancer drug targeting BRCA.

 

Not only can it be used for secondary or higher therapy, but recently it is expanding its scope to maintenance therapy.

 

The SOLO-1 study is a phase III demonstrating the efficacy of Lynparza as a primary maintenance therapy for advanced ovarian cancer with BRCA mutations.

 

At the third year of study, Lynparza reduced the risk of disease progression and death by 70% compared to placebo.

 

Subsequent SOLO-2 studies demonstrated the effectiveness of Lynparza as a second-line maintenance therapy.

 

A real-world study in Korea was conducted on Lynparza maintenance therapy.

 

This study shows actual clinical results in the field of BRCA mutant highly serous recurrent ovarian cancer.

 

As a result of the analysis, the median progression-free survival (mPFS) of patients taking Lynparza was 14.6 months, and the progression-free survival rate (PFS) was 42.4% at 24 months of treatment.

 

This data is similar to the results of the Lynparza STUDY-19 study, which did not include Koreans, and Professor Kim interpreted it to mean that the effect of Lynparza appeared at least the same or better than the clinical trial of Korean patients.

 

In particular, Professor Kim viewed Lynparza as the best option for patients with BRCA mutations.

 

Currently, Zejula, the competitive drug, can be used as a first-line maintenance therapy for ovarian cancer patients regardless of the BRCA mutations.

 

Zejula is widely used, while Lynparza provides specialized treatment options for patients with BRCA mutation and HRd positive.

 

Of course, Zejula also obtained data on BRCA mutations and HRd positive patients through subgroup analysis.

 

However, the Lynparza data dominate when it comes to drug selection.

 

Professor Kim said, "All-comer (Zejula) drugs also have subgroup analysis data, but there is definitely a difference in mortality risk (HR)." "When it comes to patients with BRCA mutant ovarian cancer, Lynparza is a breakthrough without a choice.

 

The benefits they receive are completely different," he said.

 

What are Lynparza's future prospects?

 

Professor Kim expected that in the future, Lynparza could be used as a drug used at all stages, such as platinum-based chemotherapy at all stages.

 

He said, "According to the current data, Lynparza is a one-time use only for the 1st or 2nd phase.

 

Whether it can be used in both 1st and 3rd phases, it is necessary to secure evidence through additional research." He said, "If the recurrence occurs after a certain period of time after taking Lynparza in the future, it is expected that Lynparza can be used again."